#United States #Richmond #pharmaceuticals #Indivior #Opioid Treatment

Indivior Proposes Domiciliation Shift to the U.S.

On October 1, 2025, Indivior PLC, publicly known by its Nasdaq symbol INDV, revealed its intention to change its corporate domicile from the U.K. to the United States. This strategic move aims to establish a new parent company, Indivior Pharmaceuticals, Inc. (IPI), which will be situated above the existing U.K. parent organization.

Indivior's shift follows its recent listing on the Nasdaq Stock Exchange in June 2023 and the decision to cancel its secondary listing on the London Stock Exchange in July 2025. The board of directors believes that relocating the parent company's domicile will bolster the company's position within the U.S. market. By doing so, they aim to capitalize on the advantages offered by their U.S. stock listing, which includes:
- Expanding the company’s presence in the U.S. capital markets.
- Increasing the potential for U.S. equity indexation.
- Streamlining corporate governance while reducing overall complexity.
- Positioning Indivior as a leading U.S.-based innovator in treatments for opioid use disorder, thereby allowing for closer collaborations with public health leaders.

Transaction Process and Timeline

To facilitate this redomiciliation, Indivior plans to use a U.K. court-sanctioned scheme of arrangement (the "Scheme"). The transition will only proceed with the approval of Indivior's shareholders. Following the Scheme's effectiveness, Indivior PLC will become a wholly owned subsidiary of the newly formed IPI. The shares of IPI will be listed on Nasdaq, continuing to operate under the symbol INDV. Each shareholder currently holding shares of Indivior PLC will exchange their existing shares for newly issued IPI shares on the date set by the Scheme.

The important points regarding this transition are as follows:

• - No additional equity will be raised by IPI as a part of this process.
• - An extraordinary general meeting (EGM) will be held, requiring a majority vote from Indivior PLC shareholders to approve the Scheme.
• - The anticipated timeline for the transaction is:

- Mid-November 2025: Shareholder circular issued to provide details about the EGM.
- Early December 2025: EGM conducted in London.
- Late January 2026: The effective date of the Scheme; shares will be switched, and trading will commence for IPI shares on Nasdaq.

Shareholders are informed that no immediate action is required from them at this juncture, as details will be unfolding through the forthcoming shareholder circular.

Looking Ahead

Indivior has emphasized its commitment to empowering patients suffering from opioid use disorder (OUD) through the development of innovative medicinal treatments. The forthcoming transition aims to enhance Indivior's capacity to deliver effective therapies and engage more broadly with health professionals and authorities on tackling this urgent public health crisis.

Investors and stakeholders should be aware that the communication regarding the redomiciliation does not constitute a solicitation for shares or any form of securities, and further detailed information will be available through the investor relations section of Indivior’s website as the process evolves.

Indivior's goal remains steadfast: to transform OUD into a recognized and managed chronic disease rather than simply a human crisis. The company is poised to continue shaping its legacy in the treatment of OUD while expanding its operational footprint in the United States.

For more information about Indivior's mission and updates on this important transition, please visit Indivior’s website. Connect with Indivior via their LinkedIn page to stay informed on their advancements in opioid treatment solutions.